Call for Papers

Paper contributions to the 37th Philippine Chemistry Congress (37PCC) are now accepted. Please note that there are limited number of registrants that can be accommodated. Interested authors are encouraged to submit their papers as early as possible.

Abstract submissions for ORAL & POSTER PRESENTATIONS are accepted until 01 May 2023.

All submissions will undergo a peer-review process on the originality of the work, compliance with the format, scientific validity, accuracy and coherence of the content and completeness of the paper. The official language for the 37PCC is English.

Acceptance notification will be sent out to the corresponding author through e-mail by 01 Jun 2023. The technical papers committee, however, will endeavor to notify the author within 2 weeks of submission.

Important Notes

  1. Authors should indicate the preferred form of presentation (Oral or Poster) in the Abstract Submission Form but the Technical Papers Committee reserves the right to reassign papers if necessary.
  2. Only one presentation (oral or poster) is allowed for every registered (and paid) participant.
  3. The submission for a paper presentation does not automatically indicate the registration of a participant. Registration to the conference is a separate process.
  4. The presenting author must register as a participant (oral/poster paper presenter) and settle her/his registration fee before 28 June 2023 otherwise the accepted paper will be withdrawn from the program. Authors of accepted papers are encouraged to register as soon as possible after receipt of notice of acceptance.

Abstract Guidelines

The structured abstract should be written in English with no more than 500 words. It should include background and objectives, methods, results, conclusions, and a maximum of six (6) keywords. Chemical nomenclature should conform to IUPAC rules and measurements should be in SI units.

Note: If your abstract has figures, tables or equations, provide a DOCX file of your abstract using the template below. Filename format: Surname_Type of Presentation (e.g. Santos_Oral.docx)

For example:
NB: Section headers may be omitted and the sections can be combined into a single paragraph. The sections were highlighted here as an example.


Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice

Background: Despite considerable progress in the development of anticancer therapies, there is still a high mortality rate caused by cancer relapse and metastasis. Dormant or slow-cycling residual tumor cells are thought to be a source of tumor relapse and metastasis, and are therefore an obstacle to therapy. In this study, we assessed the drug resistance of tumor cells in mice, and investigated whether vaccination could promote survival.
Methods: The mouse colon carcinoma cell line CT-26 was treated with 5-fluorouracil to assess its sensitivity to drug treatment. Mice with colon tumors were immunized with inactivated slow-cycling CT-26 cells to estimate the efficacy of this vaccine.
Results: We identified a small population of slow-cycling tumor cells in the mouse colon carcinoma CT-26 cell line, which was resistant to conventional chemotherapy. To inhibit tumor recurrence and metastasis more effectively, treatments that selectively target the slow-cycling tumor cells should be developed to complement conventional therapies. We found that drug-treated, slow-cycling tumor cells induced a more intense immune response in vitro. Moreover, vaccination with inactivated slow-cycling tumor cells caused a reduction in tumor volume and prolonged the overall survival of tumor-bearing mice.
Conclusions: These findings suggest that targeting of slow-cycling tumor cells application using immunotherapy is a possible treatment to complement traditional antitumor therapy.
Keywords: cancer relapse; drug resistance; slow-cycling tumor cells; tumor vaccine
——————–
Sun, Q., Zhong, Y., Wu, F. et al. Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice. BMC Med 10, 172 (2012). https://doi.org/10.1186/1741-7015-10-172


Oral Presentation Guidelines

Oral presenters must be officially registered to the conference on or before 28 June 2023. Authors of accepted papers are encouraged to register as soon as possible after receipt of notice of acceptance.

Oral presenters are allotted 10-12 minutes presentation and 3 minutes Q&A.

Poster Presentation Guidelines

Poster presenters must be officially registered to the conference on or before 28 June 2023. Authors of accepted papers are encouraged to register as soon as possible after receipt of notice of acceptance.

The poster should be printed in portrait [Size: A0 (841 x 1189 millimeters or 33.110 x 46.811 inches)]. It should include the header (title, author(s), affiliation(s) and contact details), abstract, introduction, methodology, results and discussion, conclusions, and references/acknowledgements. Chemical nomenclature should conform to IUPAC rules and measurements should be in SI units.

For the abstract, use a maximum of 250 words to convey the breakthrough and highlights of the study. For the figures and tables, number them sequentially and provide an appropriate caption, place it above for tables or below for figures. Include legends and other details as necessary. Cite major references using an appropriate citation style (i.e. APA) and acknowledge funding agencies and partner institutions as necessary.

Notice of Acceptance

Notification of status (acceptance as oral or poster) will be sent out to the corresponding author through e-mail on or before 01 Jun 2023.